Sumitomo Pharma

Profilo dell'azienda

Sumitomo Pharma Co., Ltd. Manufactures, purchases, and sells pharmaceutical products for medical treatment in Japan, North America, and Asia. It offers therapeutic agents for parkinson's disease, type 2 diabetes, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia. The company also provides atypical antipsychotic, generic products, antiepileptic, atypical antipsychotic, and carbapenem antibiotic. In addition, it offers veterinary medicines, medical devices, etc. The company has collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.

Descrizione disponibile in inglese.

Dati societari

Settore

Salute

Industria

Drug Manufacturers - Specialty & Generic

Paese

Giappone

Sede

2-6-8 Doshomachi, 541-0045, Osaka

Quotazione

4506 · TSE

Indici

Nikkei 225

Valuta

JPY

ISIN

JP3495000006

Sito web

sumitomo-pharma.com